Bringing New Blood to the Anemia Market
This article was originally published in Start Up
Executive Summary
Sales of erythropoiesis-stimulating agents for treating anemia totaled approximately $11.5 billion in 2008, about $7 billion in the US. Any emerging venture expecting to sink its teeth into this huge market will need to prove its future product offers greater ease of manufacture, storage, and administration, and lower price and a better safety profile compared with the widely used biologics, while overcoming the higher barriers to approval set by the FDA.
You may also be interested in...
AstraZeneca To Share FibroGen’s Anemia Compound With Astellas, But Will Hoard China For Itself
In FibroGen’s FG-4592, AstraZeneca sees a potential strong seller in China where the privately held biotech's other pharma partner, Astellas, doesn’t already own rights.
AstraZeneca’s “Smart Risks” Include Sharing FibroGen’s Anemia Compound With Astellas
The British pharma continues to build its cardiovascular and metabolic pipeline to slow its dive off the patent cliff; in FibroGen’s FG-4592, it sees a potential strong seller in regions where the privately held biotech's other pharma partner, Astellas, doesn’t already own rights.
Palkion Inc.
CrystalGenomics Inc. and ProQuest Investments formed Palkion Inc. to identify and develop orally available anemia drugs that modulate the HIF prolyl hydroxylase enzyme system. Palkion is finishing up preclinical toxicology on its lead candidate for anemia associated with chronic kidney disease.